7th DDR Inhibitors Summit The Colonnade Hotel, Boston

DDR inhibitor development is evolving rapidly, marked by the continuous emergence of new targets. AstraZeneca and Merck reaffirm their commitment to DDR inhibitors, yet more pharmaceutical companies like Roche and Gilead are diving into this therapeutic strategy; biotech companies like Artios and IDEAYA remain dedicated to delivering safe and effective treatments to patients.

The unmet need for cancer therapies reinforces the critical importance for the community to unite at the 7th Annual DDR Inhibitors Summit in Boston, January 2024, to advance first-in-class oncology treatments for patients.

This year’s conference has undergone a renovation to maximize your experience, featuring a new biomarkers pre-conference focus day with the goal of demystifying patient stratification and target ID. Two tracks for the main conference days follow, covering early discovery of next-generation targets and clinical updates.

Join 150 peers in oncology innovation, synthetic lethality, medicinal chemistry, and clinical development, at the exclusive DDR Inhibitors conference – the sole industry-led event providing unmatched depth and insight into your challenges.

Speakers: Alan D’Andrea, Director – Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Alex gaither, Vice President – Biology, Ex Scientia, Alison Karst, Senior Research Scientist – Oncology Biology, Gilead Sciences and More.